FDA Grants Traditional Approval to Retevmo (selpercatinib) for Medullary Thyroid Cancer with a RET Mutation

On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer…Original Article